Neuromuscular Complications in COVID-19: A Review of the Literature

Authors

  • Tiffany H. Pike-Lee, MD Neuromuscular Center, Department of Neurology, Neurological Institute, Cleveland Clinic, Cleveland, Ohio
  • Yuebing Li, MD, PhD Neuromuscular Center, Department of Neurology, Neurological Institute, Cleveland Clinic, Cleveland, Ohio
  • Gil I. Wolfe, MD Department of Neurology, Jacobs School of Medicine and Biomedical Sciences, University at Buffalo/SUNY, Buffalo, New York

DOI:

https://doi.org/10.17161/rrnmf.v1i3.13816

Keywords:

COVID-19, Viral infections, Pneumonia, Neuromuscular complications, Immunosuppression, Guillain-Barré syndrome, Miller Fisher syndrome, Myelitis, Myasthenia gravis

Abstract

Coronavirus disease of 2019 (COVID-19) belongs to the betacoronavirus family which is known to cross species barriers and lead to high pathogenicity. There is rapidly growing evidence that COVID-19 infection can be associated with neuromuscular complications. A comprehensive literature review was conducted evaluating articles published related to neuromuscular complications in COVID-19.  In this review we focus our discussion on two ways that COVID-19 critically impacts neuromuscular medicine: (1) serious complications and outcomes associated with the viral infection and; (2) management considerations for neuromuscular patients on immunotherapies during the COVID-19 pandemic.  

Downloads

Download data is not yet available.

References

1. Helmy YA, Fawzy M, Elaswad A, Sobieh A, Kenney SP, Shehata AA. The COVID-19 Pandemic: A Comprehensive Review of Taxonomy, Genetics, Epidemiology, Diagnosis, Treatment, and Control. J Clin Med. 2020;9(4):1225. Published 2020 Apr 24. doi:10.3390/jcm9041225

2. World Health Organization.int. 2020. World Health Organization Coronavirus Disease (COVID-19) Situation Report – 150. [online] Available at: <https://www.who.int/docs/default-source/coronaviruse/situation-reports/20200618-covid-19-sitrep-150.pdf?sfvrsn=aa9fe9cf_2> [Accessed 23 June 2020].


3. Ahmad, I. and Rathore, F., 2020. Neurological manifestations and complications of COVID-19: A literature review. Journal of Clinical Neuroscience, 77, pp.8-12. doi:10.1016/j.jocn.2020.05.017

4. Mao L, Jin H, Wang M, et al. Neurologic manifestations of hospitalized patients with coronavirus disease 2019 in Wuhan, China [published online ahead of print April 10, 2020]. JAMA Neurol. 2020. https://doi.org/10.1001/jamaneurol.2020.1127.

5. Guidon AC, Amato AA. COVID-19 and neuromuscular disorders. Neurology. 2020;94(22):959-969. doi:10.1212/wnl.0000000000009566

6. Ahmad, I. and Rathore, F., 2020. Neurological manifestations and complications of COVID-19: A literature review. Journal of Clinical Neuroscience, 77, pp.8-12. doi:10.1212/WNL.0000000000009566

7. Alberti, P., Beretta, S., Piatti, M., Karantzoulis, A., Piatti, M., Santoro, P., Viganò, M., Giovannelli, G., Pirro, F., Montisano, D., Appollonio, I. and Ferrarese, C., 2020. Guillain-Barré syndrome related to COVID-19 infection. Neurology - Neuroimmunology Neuroinflammation, 7(4), p.e741. doi:10.1212/NXI.0000000000000741

8. Assini, A., Benedetti, L., Di Maio, S., Schirinzi, E. and Del Sette, M., 2020. New clinical manifestation of COVID-19 related Guillain-Barrè syndrome highly responsive to intravenous immunoglobulins: two Italian cases. Neurological Sciences,. doi.org/10.1007/s10072-020-04484-5

9. Camdessanche, J., Morel, J., Pozzetto, B., Paul, S., Tholance, Y. and Botelho-Nevers, E., 2020. COVID-19 may induce Guillain–Barré syndrome. Revue Neurologique, 176(6), pp.516-518.

10. Coen, M., Jeanson, G., Culebras Almeida, L., Hübers, A., Stierlin, F., Najjar, I., Ongaro, M., Moulin, K., Makrygianni, M., Leemann, B., Kronig, I., Bertrand, J., Reny, J., Schibler, M. and Serratrice, J., 2020. Guillain-Barré syndrome as a complication of SARS-CoV-2 infection. Brain, Behavior, and Immunity, 87, pp.111-112. doi.org/10.1016/j.bbi.2020.04.074

11. Helbok, R., Beer, R., Löscher, W., Boesch, S., Reindl, M., Hornung, R., Schiefecker, A., Deisenhammer, F. and Pfausler, B., 2020. Guillain‐Barré syndrome in a patient with antibodies against SARS‐COV‐2. European Journal of Neurology,. doi: 10.1111/ENE.14388

12. Lascano, A., Epiney, J., Coen, M., Serratrice, J., Bernard‐Valnet, R., Lalive, P., Kuntzer, T. and Hübers, A., 2020. SARS‐CoV‐2 and Guillain‐Barré syndrome: AIDP variant with favorable outcome. European Journal of Neurology,. doi: 10.1111/ENE.14368

13. Oguz‐Akarsu, E., Ozpar, R., Mirzayev, H., Acet‐Ozturk, N., Hakyemez, B., Ediger, D., Karli, N., Akalın, H., Mustafaoglu, M., Armagan, E., Hunutlu, C., Urhan, A., Yilmaz, E., Kazak, E., Heper, Y., Karadag, M., Ursavas, A., Coskun, F., Uzaslan, E., Gorektasli, A., Demirdogen, E., Ozkalemkas, F., Celebi, S., Uncu, G., Turkkan, A., Ozcakir, A., Ozdemir, L., Ozakın, C., Kelebek, N., Duzgun, F., Bor, N., Sakarya, S., Durmaz, F., Parlak, M., Gullulu, M., Goren, S., Aydinlar, A., Durak, K., İscimen, R., Akova, B., Adim, S., Ozcakir, S., Payaslioglu, A., Oral, H., Kaya, E., Kiristioglu, I. and Ali, R., 2020. Guillain–Barré Syndrome in a Patient with Minimal Symptoms of COVID‐19 Infection. Muscle & Nerve,. Doi.org/10.1002/mus.26992

14. Ottaviani, D., Boso, F., Tranquillini, E., Gapeni, I., Pedrotti, G., Cozzio, S., Guarrera, G. and Giometto, B., 2020. Early Guillain-Barré syndrome in coronavirus disease 2019 (COVID-19): a case report from an Italian COVID-hospital. Neurological Sciences, 41(6), pp.1351-1354. doi.org/10.1007/s10072-020-04449-8

15. Rana, S., Lima, A., Chandra, R., Valeriano, J., Desai, T., Freiberg, W. and Small, G., 2020. Novel Coronavirus (COVID-19)-Associated Guillain–Barré Syndrome. Journal of Clinical Neuromuscular Disease, 21(4), pp.240-242.doi.10.1097/cnd.0000000000000309


16. Padroni, M., Mastrangelo, V., Asioli, G., Pavolucci, L., Abu-Rumeileh, S., Piscaglia, M., Querzani, P., Callegarini, C. and Foschi, M., 2020. Guillain-Barré syndrome following COVID-19: new infection, old complication?. Journal of Neurology,. doi.org/10.1007/s00415-020-09849-6

17. Scheidl, E., Canseco, D., Hadji‐Naumov, A. and Bereznai, B., 2020. Guillain‐Barr é syndrome during SARS‐CoV ‐2 pandemic: A case report and review of recent literature. Journal of the Peripheral Nervous System, 25(2), pp.204-207. doi.org/ 10.1111/jns.12382

18. Sedaghat Z, Karimi N. Guillain Barre syndrome associated with COVID-19 infection: A case report. Journal of Clinical Neuroscience. 2020;76:233-235. doi:10.1016/j.jocn.2020.04.062
19. Su XW, Palka SV, Rao RR, Chen FS, Brackney CR, Cambi F. SARS‐CoV ‐2–associated Guillain‐Barré syndrome with dysautonomia. Muscle & Nerve. 2020. doi:10.1002/mus.26988

20. Otmani HE, Moutawakil BE, Rafai M-A, et al. Covid-19 and Guillain-Barré syndrome: More than a coincidence! Revue Neurologique. 2020;176(6):518-519. doi:10.1016/j.neurol.2020.04.007


21. Toscano G, Palmerini F, Ravaglia S, et al. Guillain–Barré Syndrome Associated with SARS-CoV-2. New England Journal of Medicine. 2020. doi:10.1056/nejmc2009191

22. Virani A, Rabold E, Hanson T, et al. Guillain-Barré Syndrome associated with SARS-CoV-2 infection. IDCases. 2020;20. doi:10.1016/j.idcr.2020.e00771

23. Zhao H, Shen D, Zhou H, Liu J, Chen S. Guillain-Barré syndrome associated with SARS-CoV-2 infection: causality or coincidence? The Lancet Neurology. 2020;19(5):383-384. doi:10.1016/s1474-4422(20)30109-5

24. Gutiérrez-Ortiz C, Méndez A, Rodrigo-Rey S, et al. Miller Fisher Syndrome and polyneuritis cranialis in COVID-19. Neurology. 2020. doi:10.1212/wnl.0000000000009619

25. Reyes‐Bueno JA, García‐Trujillo L, Urbaneja P, et al. Miller‐Fisher syndrome after SARS‐CoV‐2 infection. European Journal of Neurology. 2020. doi:10.1111/ene.14383

26. Geleris J, Sun Y, Platt J, Zucker J, Baldwin M, Hripcsak G, et al. Observational study of Hydroxychloroquine in hospitalized patients with Covid-19. N Engl J Med. 2020. Available online on May 7, 2020. https://doi.org/10.1056/NEJMoa2012410.

27. Metlay JP, Waterer GW, Long AC, et al. Diagnosis and treatment of adults with community-acquired pneumonia: an official clinical practice guideline of the American Thoracic Society and Infectious Disease Society of America. Am J Respir Crit Care Med. 2019;200(7):e45-e67. doi:10.1164/rccm.201908-1581ST

28. Zhang G, Zhang J, Wang B, Zhu X, Wang Q, Qiu S. Analysis of clinical characteristics and laboratory findings of 95 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a retrospective analysis. 2020. doi:10.21203/rs.3.rs-17712/v1

29. Romero-Sánchez CM, Díaz-Maroto I, Fernández-Díaz E, et al. Neurologic manifestations in hospitalized patients with COVID-19: The ALBACOVID registry. Neurology. 2020. doi:10.1212/wnl.0000000000009937

30. Jin M, Tong Q. Rhabdomyolysis as Potential Late Complication Associated with COVID-19. Emerging Infectious Diseases. 2020;26(7):1618-1620. doi:10.3201/eid2607.200445

31. Guan W, Ni Z, Hu Y, et al.: Clinical characteristics of coronavirus disease 2019 in China. N.Engl J Med. 2020, 10.1056/NEJMoa2002032.

32. Gummi RR, Kukulka NA, Deroche CB, Govindarajan R. Factors associated with acute exacerbations of myasthenia gravis. Muscle & Nerve. 2019;60(6):693-699. doi:10.1002/mus.26689

33. Gilhus NE, Romi F, Hong Y, Skeie GO. Myasthenia gravis and infectious disease. J Neurol. 2018;265(6):1251-1258. doi:10.1007/s00415-018-8751-9

34. Jacob S, Muppidi S, Guidon A, et al. Guidance for the management of myasthenia gravis (MG) and Lambert-Eaton myasthenic syndrome (LEMS) during the COVID-19 pandemic. Journal of the Neurological Sciences. 2020;412:116803. doi:10.1016/j.jns.2020.116803

35. Anand P, Slama MCC, Kaku M, et al. COVID ‐19 in patients with myasthenia gravis. Muscle & Nerve. 2020. doi:10.1002/mus.26918

36. Zhao K, Huang J, Dai D, Feng Y, Liu L, Nie S. Acute myelitis after SARS-CoV-2 infection: a case report. 2020. doi:10.1101/2020.03.16.20035105

37. Munz M, Wessendorf S, Koretsis G, et al. Acute transverse myelitis after COVID-19 pneumonia. Journal of Neurology. 2020. doi:10.1007/s00415-020-09934-w

38. Manji H, Carr AS, Brownlee WJ, Lunn MP. Neurology in the time of COVID-19. Journal of Neurology, Neurosurgery & Psychiatry. 2020;91(6):568-570. doi:10.1136/jnnp-2020-323414

39. Solé G, Salort-Campana E, Pereon Y, et al. Guidance for the care of neuromuscular patients during the COVID-19 pandemic outbreak from the French Rare Health Care for Neuromuscular Diseases Network. Revue Neurologique. 2020;176(6):507-515. doi:10.1016/j.neurol.2020.04.004

40. Montalvan V, Lee J, Bueso T, Toledo JD, Rivas K. Neurological manifestations of COVID-19 and other coronavirus infections: A systematic review. Clinical Neurology and Neurosurgery. 2020;194:105921. doi:10.1016/j.clineuro.2020.105921

41. Dalakas MC. Guillain-Barré syndrome: The first documented COVID-19–triggered autoimmune neurologic disease. Neurology - Neuroimmunology Neuroinflammation. 2020;7(5). doi:10.1212/nxi.0000000000000781

42. Delly F, Syed MJ, Lisak RP, Zutshi D. Myasthenic crisis in COVID-19. Journal of the Neurological Sciences. 2020;414:116888. doi:10.1016/j.jns.2020.116888

43. Hamming I, Timens W, Bulthuis ML, Lely AT, Navis G, van Goor H. Tissue distribution of ACE2 protein, the functional receptor for SARS coronavirus: a first step in understanding SARS pathogenesis. J Pathol. 2004;203(2):631-637. doi:10.1002/path.1570

44. Ramaswamy SB, Govindarajan R. COVID-19 in Refractory Myasthenia Gravis- A Case Report of Successful Outcome. Journal of Neuromuscular Diseases. 2020;7(3):361-364. doi:10.3233/jnd-200520

Downloads

Published

2020-07-17

How to Cite

Pike-Lee, T., Li, Y., & Wolfe, G. (2020). Neuromuscular Complications in COVID-19: A Review of the Literature. RRNMF Neuromuscular Journal, 1(3), 13-21. https://doi.org/10.17161/rrnmf.v1i3.13816

Issue

Section

Looking Back and Looking Forward at Stuff (Reviews)